Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204

Stock Information for Marvel Biosciences Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Marvel Biosciences Corp.

Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204
Toronto Stock Exchange, Marvel Biosciences Corp., The View from the C-Suite
Marvel Biosciences Announces Grant of Deferred Share Units
Marvel Biosciences Announces Acceleration of Warrant Expiry Date
Marvel Biosciences Granted Chinese Patent for Lead Therapeutic Candidate MB-204
Marvel Biosciences Announces Grant of Deferred Share Units
Marvel Biosciences Announces Closing of Private Placement
Marvel Biosciences Announces Closing of Second Tranche of Private Placement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.